DOCSLIB.ORG

2007 National Home and Hospice Care Survey Medications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2007 National Home and Hospice Care Survey Medications Drug Characteristics and Estimates for Medications Taken by Current Home Health Care Patients in 2007 NHHCS Unweighted Weighted Number Composition Prescription DEA Status Number of of PMCODE Drug Name Status Code Status Code Code Drug Mentions* Drug Mentions** Rate per 10000 02805 ASPIRIN 1 1 6 1172 363099 2487.07 17165 LASIX 1 1 6 1044 303879 2081.44 32905 TYLENOL 1 2 6 937 278253 1905.91 92164 LISINOPRIL 1 1 6 634 206047 1411.33 07930 COUMADIN 1 1 6 557 179252 1227.80 97020 LIPITOR 1 1 6 454 158226 1083.78 99133 ALBUTEROL 1 1 6 473 152685 1045.83 07265 COLACE 1 2 6 460 145877 999.19 98086 PLAVIX 1 1 6 431 131227 898.85 93187 NORVASC 1 1 6 328 128374 879.31 19825 MULTIPLE VITAMINS 1 1 6 397 116443 797.58 19840 MULTIVITAMIN 1 1 6 415 114614 785.06 00042 PROTONIX 1 1 6 357 114257 782.61 19218 METOPROLOL 1 1 6 363 112706 771.99 95133 METFORMIN 1 1 6 297 110494 756.84 30395 SYNTHROID 1 1 6 394 109633 750.94 93156 TOPROL XL 1 1 6 347 107023 733.06 01002 NEXIUM 1 1 6 346 103877 711.51 91063 ATENOLOL 1 1 6 325 102962 705.25 22315 OXYGEN 1 1 6 423 101929 698.17 24653 POTASSIUM CHLORIDE 1 1 6 363 95528 654.33 95122 PREVACID 1 1 6 302 94518 647.41 01034 ADVAIR DISKUS 2 1 6 300 92594 634.23 01214 LANTUS 1 1 6 272 90994 623.27 34110 VICODIN 2 1 3 243 87037 596.17 97036 DIOVAN 1 1 6 210 86621 593.32 08470 DARVOCET-N 2 1 4 319 85810 587.76 13118 FUROSEMIDE 1 1 6 295 85798 587.68 97016 ARICEPT 1 1 6 218 85650 586.67 93237 SIMVASTATIN 1 1 6 255 82427 564.59 97142 COREG 1 1 6 251 81954 561.35 93181 ZOCOR 1 1 6 267 81903 561.00 91043 PRILOSEC 1 1 6 315 81343 557.16 12865 FOLIC ACID 1 1 6 216 77861 533.31 12490 FERROUS SULFATE 1 2 6 261 76661 525.09 93347 AMBIEN 1 1 4 226 76407 523.36 91096 OMEPRAZOLE 1 1 6 257 75577 517.67 02153 VITAMIN B12/FOLIC ACID 2 2 6 254 74424 509.77 24890 PREDNISONE 1 1 6 270 73585 504.03 94099 NEURONTIN 1 1 6 219 71641 490.71 17370 LEVOTHYROXINE 1 1 6 240 70234 481.07 34520 VITAMIN C 1 1 6 280 70159 480.56 02119 LEXAPRO 1 1 6 236 67257 460.68 93183 ZOLOFT 1 1 6 200 66802 457.57 14930 HYDROCHLOROTHIAZIDE 1 1 6 205 66489 455.42 16710 KLOR-CON 1 1 6 172 65803 450.72 95183 FOSAMAX 1 1 6 181 65570 449.13 97126 FLOMAX 1 1 6 209 64693 443.12 98038 SINGULAIR 1 1 6 191 63193 432.84 17888 LORAZEPAM 1 1 4 201 63078 432.06 00100 A.S.A. 1 1 6 293 62910 430.91 14955 HYDROCODONE 1 1 2 229 62641 429.06 05415 CALCIUM 1 3 6 253 61985 424.57 09545 DIGOXIN 1 1 6 185 58248 398.97 35023 XANAX 1 1 4 201 58071 397.76 92180 LORTAB 2 1 3 244 56269 385.42 23385 PERCOCET-5 2 1 2 182 56255 385.32 99080 MIRALAX 1 1 6 223 55495 380.12 91081 GLIPIZIDE 1 1 6 150 54402 372.63 04042 SPIRIVA 1 1 6 174 51548 353.08 04011 NAMENDA 1 1 6 121 51321 351.53 99090 ACTOS 1 1 6 154 50728 347.47 15395 IBUPROFEN 1 2 6 228 50234 344.08 24650 POTASSIUM 1 3 6 236 49396 338.34 31997 TRAZODONE 1 1 6 164 48789 334.18 06985 CLONIDINE 1 1 6 130 48546 332.52 19375 MILK OF MAGNESIA 1 2 6 196 48459 331.92 29250 SPIRONOLACTONE 1 1 6 155 47740 327.00 02223 ZETIA 1 1 6 117 47733 326.95 17885 LOPRESSOR 1 1 6 143 47436 324.92 02900 ATIVAN 1 1 4 151 46544 318.81 21160 NITROGLYCERIN 1 1 6 151 46500 318.51 26255 REGLAN 1 1 6 167 45765 313.47 01030 ALLOPURINOL 1 1 6 162 45569 312.13 03423 BACLOFEN 1 1 6 183 45283 310.17 *Refer to Supplemental Drug Information section in Technical Notes. **Refer to Supplemental Drug Information section in Technical Notes. Drug Characteristics and Estimates for Medications Taken by Current Home Health Care Patients in 2007 NHHCS Unweighted Weighted Number Composition Prescription DEA Status Number of of PMCODE Drug Name Status Code Status Code Code Drug Mentions* Drug Mentions** Rate per 10000 94114 GABAPENTIN 1 1 6 149 43904 300.72 27770 SENNA 1 2 6 171 43796 299.98 91062 ALPRAZOLAM 1 1 4 139 43276 296.42 41780 ZANTAC 1 1 6 154 43266 296.35 93305 GLYBURIDE 1 1 6 149 42798 293.15 94070 EFFEXOR 1 1 6 85 42143 288.66 21695 NYSTATIN 1 1 6 141 40679 278.63 22303 OXYCODONE HCL 1 1 2 138 40317 276.15 96041 TRAMADOL 1 1 6 143 40103 274.69 15680 INSULIN 1 2 6 120 39798 272.60 00260 ACETAMINOPHEN 1 2 6 151 39366 269.64 34775 WARFARIN 1 1 6 129 39055 267.51 95005 FLONASE 1 1 6 93 38255 262.03 03187 CRESTOR 1 1 6 102 38229 261.85 04051 CYMBALTA 1 1 6 128 37885 259.50 03905 BENADRYL 1 2 6 140 37820 259.05 91072 DILTIAZEM HCL 1 1 6 132 37358 255.89 18555 MECLIZINE 1 1 6 147 37337 255.74 93211 AMIODARONE 1 1 6 105 36940 253.02 97105 COMBIVENT 2 1 6 137 36936 253.00 99106 XOPENEX 1 1 6 119 36503 250.03 97168 SEROQUEL 1 1 6 97 36192 247.90 34565 VITAMIN D 1 1 6 115 36163 247.70 02209 NOVOLOG 1 1 6 96 35893 245.85 00313 DIGITEK 1 1 6 111 35707 244.58 27368 SALINE 1 1 6 122 35660 244.26 93212 PAXIL 1 1 6 108 35125 240.59 05097 LYRICA 1 1 5 119 34784 238.26 60775 K-DUR 1 1 6 96 34437 235.88 94031 IMDUR 1 1 6 112 34361 235.36 99002 CELEBREX 1 1 6 132 34120 233.71 96027 DOCUSATE SODIUM 1 2 6 140 34088 233.49 95152 COZAAR 1 1 6 127 33418 228.90 94117 LOVENOX 1 1 6 76 33269 227.88 10575 DULCOLAX 1 2 6 132 33227 227.59 02982 ATROVENT 1 1 6 97 32869 225.14 61160 PEPCID 1 1 6 95 32766 224.43 91088 LOVASTATIN 1 1 6 82 32603 223.32 97170 CENTRUM SILVER 1 1 6 119 32282 221.12 16105 ISOSORBIDE 1 1 6 97 32220 220.69 04114 VYTORIN 2 1 6 102 32201 220.56 98115 CELEXA 1 1 6 103 31930 218.71 00206 ACTONEL 1 1 6 97 31814 217.91 97045 LEVAQUIN 1 1 6 98 31556 216.15 23755 PHENERGAN 1 1 6 120 31405 215.11 03188 MUCINEX 1 2 6 94 31187 213.62 06980 CLONAZEPAM 1 1 4 92 31130 213.23 10087 DOCUSATE 1 2 6 108 31053 212.70 27785 SENOKOT 1 2 6 98 30970 212.13 41800 HCTZ 1 1 6 116 30802 210.98 41850 KCL 1 1 6 103 30643 209.89 93257 LORATADINE 1 2 6 108 30551 209.26 19675 MOTRIN 1 2 6 82 30270 207.34 95050 ULTRAM 1 1 6 79 30103 206.19 91000 ALBUTEROL SULFATE 1 1 6 100 29540 202.34 95111 GLUCOPHAGE 1 1 6 78 29149 199.66 02079 NITROGLYCERIN SUBLINGUAL 1 1 6 86 28546 195.53 98158 TRICOR 1 1 6 62 28424 194.69 22287 OXYBUTYNIN CHLORIDE 1 1 6 75 28373 194.34 99189 CALCIUM W/ VITAMIN D 2 2 6 130 28090 192.40 33555 VALIUM 1 1 4 86 27928 191.30 91099 RANITIDINE 1 1 6 107 27720 189.87 14840 HYDRALAZINE 1 1 6 61 27704 189.76 34575 VITAMIN E 1 2 6 115 27504 188.39 60790 KLONOPIN 1 1 4 78 27491 188.30 97145 AVAPRO 1 1 6 46 27454 188.05 99030 AVANDIA 1 1 6 84 27255 186.69 15870 IRON PREPARATION 1 3 6 108 27198 186.29 09585 DILANTIN 1 1 6 90 27194 186.27 93193 SERTRALINE 1 1 6 82 27115 185.73 01530 AMITRIPTYLINE 1 1 6 84 26908 184.31 94158 RISPERDAL 1 1 6 83 26874 184.08 97174 BABY ASPIRIN 1 1 6 52 26837 183.82 32920 TYLENOL NO. 3 2 1 3 68 26463 181.26 98065 DETROL 1 1 6 79 26241 179.74 *Refer to Supplemental Drug Information section in Technical Notes. **Refer to Supplemental Drug Information section in Technical Notes. Drug Characteristics and Estimates for Medications Taken by Current Home Health Care Patients in 2007 NHHCS Unweighted Weighted Number Composition Prescription DEA Status Number of of PMCODE Drug Name Status Code Status Code Code Drug Mentions* Drug Mentions** Rate per 10000 97017 HUMALOG 1 1 6 84 26200 179.46 97049 TOPAMAX 1 1 6 50 26081 178.64 99026 GLUCOSAMINE 1 2 6 90 25765 176.48 96167 XALATAN 1 1 6 79 25669 175.82 93396 AMLODIPINE 1 1 6 75 25442 174.27 96122 REMERON 1 1 6 75 25318 173.42 01057 DETROL LA 1 1 6 78 25108 171.98 02279 PULMICORT 1 1 6 90 25012 171.32 06100 CENTRUM 1 1 6 70 24746 169.50 93224 CLARITIN 1 2 6 88 24643 168.79 91074 ENALAPRIL 1 1 6 81 24589 168.42 99098 NITROQUICK 1 1 6 65 24362 166.87 18205 MAGNESIUM OXIDE 1 1 6 82 24042 164.68 92003 ALTACE 1 1 6 82 23971 164.19 61625 TRIAMTERENE W/HCTZ 2 1 6 67 23786 162.92 06839 CIPRO 1 1 6 92 23571 161.45 08836 DEPAKOTE 1 1 6 74 23226 159.09 96022 ZYRTEC 1 1 6 97 22946 157.17 02036 EXTRA STRENGTH TYLENOL 1 2 6 48 22913 156.94 99028 TYLENOL ARTHRITIS 1 2 6 80 22749 155.82 16975 LACTULOSE 1 1 6 96 22726 155.66 96174 ALLEGRA 1 1 6 64 22270 152.54 25365 PROMETHAZINE 1 1 6 75 22171 151.86 91084 IPRATROPIUM BROMIDE 1 1 6 80 22050 151.03 30756 TEMAZEPAM 1 1 4 52 21912 150.09 61045 NOVOLIN 1 2 6 65 21764 149.07 00184 KEPPRA 1 1 6 65 21710 148.70 33858 VERAPAMIL 1 1 6 56 21632 148.17 99074 CITALOPRAM 1 1 6 66 21481 147.14 22110 OS-CAL 1 2 6 55 21005 143.88 96173 ZYPREXA 1 1 6 52 20916 143.27 34625 VITAMIN(S) 1 1 6 64 20910 143.22 28080 SINEMET 2 1 6 54 20805 142.51 02042 DUONEB 2 1 6 137 20546 140.73 97056 MIRTAZAPINE 1 1 6 48 20461 140.15 97047 MAGNESIUM 1 3 6 67 20430 139.94 94004 PAROXETINE 1 1 6 46 20407 139.78 17115 LANOXIN 1 1 6 93 20343 139.34 96109 OXYCONTIN 1 1 2 71 20179 138.22 25674 PROZAC 1 1 6 95 20123 137.83 09995 DITROPAN 1 1 6 59 20036 137.24 19208 METOCLOPRAMIDE 1 1 6 78 19831 135.83 89038 HYDROCODONE BITARTRATE 2 1 3 90 19575 134.08 15545 IMODIUM 1 1 6 81 19493 133.52 18125 MAALOX 2 2 6 55 19372 132.69 18930 METAMUCIL 1 2 6 79 19360 132.61 24950 PREMARIN 1 1 6 72 19319 132.33 04370 BISACODYL 1 2 6 82 19290 132.13 04079 GLYCOLAX 1 1 6 63 19229 131.71 97085 TORSEMIDE 1 1 6 30 19142 131.11 00102 ISOSORBIDE MONONITRATE 1 1 6 65 18969 129.93 26453 RESTORIL 1 1 4 64 18870 129.25 61605 WELLBUTRIN 1 1 6 59 18870 129.25 94125 ALEVE 1 1 6 90 18404 126.06 00597 ADVIL 1 2 6 58 18217 124.78 14965 HYDROCORTISONE 1 1 6 56 18061 123.71 06125 CEPHALEXIN 1 1 6 50 17631 120.77 22306 OXYCODONE W/APAP 2 1 2 87 17553 120.23 93062 FISH OIL 1 2 6 63 17436 119.43 97152 MIRAPEX 1 1 6 38 17383 119.07 12635 FLEXERIL 1 1 6 74 17264 118.25 93348 PHOSLO 1 1 6 37 17154 117.50 09370 DIAZEPAM 1 1 4 79 17029 116.64 15100 HYDROXYZINE 1 1 6 56 16986 116.35 17365 LEVOTHROID 1 1 6 66 16906 115.80 20290 NAPROXEN 1 1 6 67 16807 115.12 97150 REQUIP 1 1 6 60 16713 114.48 10975 ECOTRIN 1 1 6 37 16645 114.01 00004 LIDODERM PATCH 1 1 6 63 16525 113.19 95144 LOTREL 2 1 6 66 16427 112.52 01022 METOPROLOL TARTRATE 1 1 6 64 16318 111.77 99172 NOVOLIN 70/30 2 2 6 47 16260 111.37 00830 ALDACTONE 1 1 6 55 16156 110.66 05405 CALCIUM CARBONATE 1 2 6 49 16151 110.63 92076 PRAVACHOL 1 1 6 33 16019 109.72 *Refer to Supplemental Drug Information section in Technical Notes.
Load more

Recommended publications
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • Pharmacokinetic Drug–Drug Interactions Among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients
    International Journal of Molecular Sciences Review Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients Marta Kara´zniewicz-Łada 1 , Anna K. Główka 2 , Aniceta A. Mikulska 1 and Franciszek K. Główka 1,* 1 Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 60-781 Pozna´n,Poland; [email protected] (M.K.-Ł.); [email protected] (A.A.M.) 2 Department of Bromatology, Poznan University of Medical Sciences, 60-354 Pozna´n,Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-(0)61-854-64-37 Abstract: Anti-epileptic drugs (AEDs) are an important group of drugs of several generations, rang- ing from the oldest phenobarbital (1912) to the most recent cenobamate (2019). Cannabidiol (CBD) is increasingly used to treat epilepsy. The outbreak of the SARS-CoV-2 pandemic in 2019 created new challenges in the effective treatment of epilepsy in COVID-19 patients. The purpose of this review is to present data from the last few years on drug–drug interactions among of AEDs, as well as AEDs with other drugs, nutrients and food. Literature data was collected mainly in PubMed, as well as google base. The most important pharmacokinetic parameters of the chosen 29 AEDs, mechanism of action and clinical application, as well as their biotransformation, are presented. We pay a special attention to the new potential interactions of the applied first-generation AEDs (carba- Citation: Kara´zniewicz-Łada,M.; mazepine, oxcarbazepine, phenytoin, phenobarbital and primidone), on decreased concentration Główka, A.K.; Mikulska, A.A.; of some medications (atazanavir and remdesivir), or their compositions (darunavir/cobicistat and Główka, F.K.
    [Show full text]
  • DESCRIPTION CLINICAL PHARMACOLOGY Mechanism Of
    NDA 20-844/ Topamav Sprinkle Capsules Approved Labeling Text Version: 10/26/98 DESCRIPTION Topiramate is a sulfamate-substituted monosaccharide that is intended for use as an antiepileptic drug. TOPAMAX@ (topiramate capsules) Sprinkle Capsules are available as I5 mg, 25 mg and 50mg sprinkle capsules for oral administration as whole capsules or for opening and sprinkling onto soft food. Topiramate is a white crystalline powder with a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and hawng a pH of 9 to IO. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3. Topiramate has the molecular formula C,,H,,NO,S and a molecular weight of 339.37. Topiramate is designated chemically as 2,3:4,5-Di-O-isopropylidene-~- D-fructopyranose sulfamate and has the following structural formula: H3C CH3 TOPAMAX” (topiramate capsules) Sprinkle Capsules contain topiramate coated beads in a hard gelatin capsule. The inactive ingredients are: sugar spheres (sucrose and starch), povidone, cellulose acetate, gelatin, silicone dioxide, sodium lauryl sulfate, titanium dioxide, and black pharmaceutical ink. CLINICAL PHARMACOLOGY Mechanism of Action: The precise mechanism by which topiramate exerts its antiseizure effect is unknown; however, electrophysiological and biochemical studies of the effects of topiramate on cultured neurons have revealed three properties that may contribute to topiramate’s antiepileptic efficacy. First, action potentials elicited repetitively by a sustained depolarization of the neurons are blocked by topiramate in a time-dependent manner, suggestive of a state-dependent sodium channel blocking action.
    [Show full text]
  • Updates in Pediatric Dermatology
    Peds Derm Updates ELIZABETH ( LISA) SWANSON , M D ADVANCED DERMATOLOGY COLORADO ROCKY MOUNTAIN HOSPITAL FOR CHILDREN [email protected] Disclosures Speaker Sanofi Regeneron Amgen Almirall Pfizer Advisory Board Janssen Powerpoints are the peacocks of the business world; all show, no meat. — Dwight Schrute, The Office What’s New In Atopic Dermatitis? Impact of Atopic Dermatitis Eczema causes stress, sleeplessness, discomfort and worry for the entire family Treating one patient with eczema is an example of “trickle down” healthcare Patients with eczema have increased risk of: ADHD Anxiety and Depression Suicidal Ideation Parental depression Osteoporosis and osteopenia (due to steroids, decreased exercise, and chronic inflammation) Impact of Atopic Dermatitis Sleep disturbances are a really big deal Parents of kids with atopic dermatitis lose an average of 1-1.5 hours of sleep a night Even when they sleep, kids with atopic dermatitis don’t get good sleep Don’t enter REM as much or as long Growth hormone is secreted in REM (JAAD Feb 2018) Atopic Dermatitis and Food Allergies Growing evidence that food allergies might actually be caused by atopic dermatitis Impaired barrier allows food proteins to abnormally enter the body and stimulate allergy Avoiding foods can be harmful Proper nutrition is important Avoidance now linked to increased risk for allergy and anaphylaxis Refer severe eczema patients to Allergist before 4-6 mos of age to talk about food introduction Pathogenesis of Atopic Dermatitis Skin barrier
    [Show full text]
  • Chapter 25 Mechanisms of Action of Antiepileptic Drugs
    Chapter 25 Mechanisms of action of antiepileptic drugs GRAEME J. SILLS Department of Molecular and Clinical Pharmacology, University of Liverpool _________________________________________________________________________ Introduction The serendipitous discovery of the anticonvulsant properties of phenobarbital in 1912 marked the foundation of the modern pharmacotherapy of epilepsy. The subsequent 70 years saw the introduction of phenytoin, ethosuximide, carbamazepine, sodium valproate and a range of benzodiazepines. Collectively, these compounds have come to be regarded as the ‘established’ antiepileptic drugs (AEDs). A concerted period of development of drugs for epilepsy throughout the 1980s and 1990s has resulted (to date) in 16 new agents being licensed as add-on treatment for difficult-to-control adult and/or paediatric epilepsy, with some becoming available as monotherapy for newly diagnosed patients. Together, these have become known as the ‘modern’ AEDs. Throughout this period of unprecedented drug development, there have also been considerable advances in our understanding of how antiepileptic agents exert their effects at the cellular level. AEDs are neither preventive nor curative and are employed solely as a means of controlling symptoms (i.e. suppression of seizures). Recurrent seizure activity is the manifestation of an intermittent and excessive hyperexcitability of the nervous system and, while the pharmacological minutiae of currently marketed AEDs remain to be completely unravelled, these agents essentially redress the balance between neuronal excitation and inhibition. Three major classes of mechanism are recognised: modulation of voltage-gated ion channels; enhancement of gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission; and attenuation of glutamate-mediated excitatory neurotransmission. The principal pharmacological targets of currently available AEDs are highlighted in Table 1 and discussed further below.
    [Show full text]
  • Misperceptions About Contraceptives Persist
    30 Women’s Health FAMILY P RACTICE N EWS • September 1, 2008 Misperceptions About Contraceptives Persist BY DOUG BRUNK trauterine device use; 50% thought IUD (SOGC). There may be inadequate in- Oral contraceptives are also safe in women San Diego Bureau failure was a major risk; and fewer than struction with regard to contraception in older than age 35 if they are healthy non- one-third would recommend an IUD as an physician-training programs, she said. smokers, and in women with systemic lu- C ALGARY, ALTA. — Physicians may option for nulliparous women, for post- “Not everybody does IUD insertions, sub- pus erythematosus provided they have no have a surprising number of misconcep- coital contraception, for women with fi- dermal progestin implant, or vasectomy.” antiphospholipid antibodies, vascular dis- tions about birth control, according to re- broids, or for women who had pelvic in- Other barriers to effective contraceptive ease, or nephritis. cent responses to a survey by 96 family flammatory disease within the last year use include exaggerated concerns about Another common exaggerated concern physicians in Kingston, Ont. (Can. Fam. Physician 2008;54:560-6). potential side effects. For example, women is that the use of oral and transdermal Contrary to evidence in the medical lit- “Only 41% of these physicians inserted with diabetes may use oral contraceptives patch contraceptives cause weight gain. erature, more than 60% of respondents IUDs,” Dr. Amanda Black said at the an- if they have no end-organ damage, said Dr. However, a recent Cochrane systematic re- thought pelvic inflammatory disease and nual meeting of the Society of Obstetri- Black of the division of general obstetrics view of randomized, controlled data con- ectopic pregnancy were major risks of in- cians and Gynaecologists of Canada and gynecology at the Ottawa Hospital.
    [Show full text]
  • Minocycline-Minocin-Fact-Sheet.Pdf
    Minocycline PATIENT FACT SHEET (Minocin) Minocycline (minocin) is an anti-inflammatory antibiotic sometimes used to treat mild rheumatoid arthritis (RA). It belongs to the group of antibiotics, called tetracycline, which are typically used to treat infections. Although RA is not thought to be caused by an infection, minocycline may improve the signs and symptoms of this disease. Because it has been studied less and may be less effective than other options, it is not as commonly prescribed in RA. WHAT IS IT? Minocycline is usually taken as a 100 mg capsule twice a day. It may be taken with food but should not be taken with other medications such as antacids or iron tablets. It has a slow onset and may take several months to work. HOW TO TAKE IT The most common side effects from this medicine rare cases, minocycline can cause drug-induced lupus, are gastrointestinal upset, dizziness, and skin rash. but this condition usually improves after stopping Patients who take this medication for a long time may the medication. notice changes in their skin color, but this usually Minocycline is passed into breast milk, so mothers resolves after stopping the medication. Some women should avoid breast-feeding in order to prevent delayed who take minocycline develop vaginal yeast infections. development of teeth and bones in their infants. Minocycline may increase sensitivity to sunlight, resulting Minocycline can increase a nursing infant’s risk of fungal in more frequent sunburns or the development of rashes infections or dizziness. Because minocycline may cause SIDE following sun exposure. Avoiding prolonged sun exposure discoloration of teeth and problems with bone growth in and sunscreen is recommended.
    [Show full text]
  • Delayed Dosing of Minocycline Plus N-Acetylcysteine Reduces Neurodegeneration in Distal Brain Regions and Restores Spatial Memor
    Manuscript bioRxiv preprint doi: https://doi.org/10.1101/2021.03.28.437090; this version posted March 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Delayed dosing of minocycline plus N-acetylcysteine reduces neurodegeneration in distal brain regions and restores spatial memory after experimental traumatic brain injury Kristen Whitney 1,2, Elena Nikulina1, Syed N. Rahman1, Alisia Alexis1 and Peter J. Bergold1,2 1Department of Physiology and Pharmacology 2Program in Neural and Behavioral Science, School of Graduate Studies State University of New York-Downstate Health Sciences University, Brooklyn NY 11215 Corresponding Author: [email protected] Department of Physiology and Pharmacology, Box 29 State University of New York – Downstate Health Sciences University 450 Clarkson Avenue Brooklyn, NY 11215 Declarations of interest: none Abbreviations: CHI- closed head injury Contra- contralateral Ipsi- ipsilateral MAP2 -microtubule associated protein 2 MINO- minocycline MN12- MINO plus NAC first dosed 12 hours after injury MN72- MINO plus NAC first dosed 72 hours after injury NAC- N-acetylcysteine TBI- Traumatic brain injury 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.28.437090; this version posted March 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Multiple drugs to treat traumatic brain injury (TBI) have failed clinical trials. Most drugs lose efficacy as the time interval increases between injury and treatment onset. Insufficient therapeutic time window is a major reason underlying failure in clinical trials.
    [Show full text]
  • Forensic Toxicology Laboratory Office of Chief Medical Examiner City of New York
    FORENSIC TOXICOLOGY LABORATORY OFFICE OF CHIEF MEDICAL EXAMINER CITY OF NEW YORK CARISOPRODOL , MEPROBAMATE and TOPIRAMATE by SOLID PHASE EXTRACTION and GAS CHROMATOGRAPHY/MASS SPECTROMETRY (Selected Ion Monitoring) PRINCIPLE Carisoprodol is a carbamate derivative first synthesized in 1959. It is primarily used as a muscle relaxant. UncontrolledMeprobamate is also a carbamate derivative used as a muscle relaxant and the primary metabolite of carisoprodol. Topiramate is a sulfamate-substituted monosaccharide used as an anticonvulsant Carisoprodol, meprobamate and topiramate are quantitated by a selected ion monitoring (SIM) method using methapyrilene as the internal standard. Carisoprodol, meprobamate and topiramate are extracted from biological specimens by solid phase extraction. Drugs are temporarily bound to a sorbent in the solid phase cartridge as the prepared sample is poured through the column. The column is washed to remove interfering compounds, followed by elution of drugs from the column. The eluate is evaporated, reconstituted and injected in the GCMS. Quantitative analysis is performed by SIM GCMS using a six point calibration curve. SAFETY The handling of all biological specimens and reagents is performed within the guidelines which are detailed in the Safety and Health manual. Copy SPECIMEN PREPARATION The procedure is routinely applied to the following biological specimens and their aliquots unless otherwise specified: Blood 0.5 mL of the undiluted specimen Urine 0.5 mL for qualitative identification Brain 0.5 mL of a 1:3 homogenate Gastric Contents 0.5 mL of a 1:10 dilution Liver 0.5 mL of a 1:5 homogenate Vitreous Humor 0.5 mL of the undiluted specimen Bile 0.5 mL of the undiluted specimen Reviewed by: Date: Page 1 of 14 T:\FINALSOP\FINAL SOP PDF\G.
    [Show full text]
  • Metabolism of Drugs in Old Rats (Ii) Metabolism in Vivo and Effect of Drugs in Old Rats
    METABOLISM OF DRUGS IN OLD RATS (II) METABOLISM IN VIVO AND EFFECT OF DRUGS IN OLD RATS RYUICHI KATO AND AKIRA TAKANAKA Department of Pharmacology, National Institute of Hygienic Sciences, Setagaya-ku, Tokyo Received for publication March 16, 1968 It is well known that the effects of some drugs in old animals quite differ from those in young animals. For example, Farner and Verzar (1) observed that the action of am phetamine to increase moter activity was more marked in young rats than in old rats and the action of hexobarbital to antagonized against the amphetamine action was more ef fective in old rats than in young rats. Moreover, the duration of hexobarbital anesthesia was longer in old rats than in young rats (2). Similarly, Petty and Karler (3) observed that anticonvulsive activity of acetazolamide and phenobarbital was more marked in old rats than in young rats. However, there is no study on the mechanism of such altered drug response in rela tion to the rate of drug metabolism. In a previous paper it was reported from our labo ratory that the activities in the oxidation and reduction of drugs and NADPH-linked elec tron transport system in liver microsomes of male and female rats were progressively decreased with aging (4). It is, therefore, of interest to investigate whether or not the metabolism in vivoof vari ous drugs is decreased in old rats in accordance with the decrease in the metabolic activi ties of liver microsomes observed in the in vitro experiments. Moreover, the relationship between the effects of drugs and the rate of in vivo metabolism of drugs in the old rats was studied.
    [Show full text]
  • Minocycline Synergizes with N-Acetylcysteine and Improves Cognition and Memory Following Traumatic Brain Injury in Rats
    Minocycline Synergizes with N-Acetylcysteine and Improves Cognition and Memory Following Traumatic Brain Injury in Rats Samah G. Abdel Baki, Ben Schwab, Margalit Haber, Andre´ A. Fenton, Peter J. Bergold* Departments of Physiology and Pharmacology, State University of New York-Downstate Medical Center, Brooklyn, New York, United States of America Abstract Background: There are no drugs presently available to treat traumatic brain injury (TBI). A variety of single drugs have failed clinical trials suggesting a role for drug combinations. Drug combinations acting synergistically often provide the greatest combination of potency and safety. The drugs examined (minocycline (MINO), N-acetylcysteine (NAC), simvastatin, cyclosporine A, and progesterone) had FDA-approval for uses other than TBI and limited brain injury in experimental TBI models. Methodology/Principal Findings: Drugs were dosed one hour after injury using the controlled cortical impact (CCI) TBI model in adult rats. One week later, drugs were tested for efficacy and drug combinations tested for synergy on a hierarchy of behavioral tests that included active place avoidance testing. As monotherapy, only MINO improved acquisition of the massed version of active place avoidance that required memory lasting less than two hours. MINO-treated animals, however, were impaired during the spaced version of the same avoidance task that required 24-hour memory retention. Co- administration of NAC with MINO synergistically improved spaced learning. Examination of brain histology 2 weeks after injury suggested that MINO plus NAC preserved white, but not grey matter, since lesion volume was unaffected, yet myelin loss was attenuated. When dosed 3 hours before injury, MINO plus NAC as single drugs had no effect on interleukin-1 formation; together they synergistically lowered interleukin-1 levels.
    [Show full text]